ATHX / Athersys, Inc. (ATHX) CEO B.J. Lehmann on Q3 2021 Results - Earnings Call Transcript

Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human li more_horizontal

The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's f more_horizontal

Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typicall more_horizontal

Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering. That public offering has Ather more_horizontal

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for more_horizontal

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for more_horizontal

Athersys, Inc. (NASDAQ:ATHX ) Q3 2022 Earnings Conference Call November 15, 2022 11:00 AM ET Company Participants Ellen Gurley – Corporate Communica more_horizontal

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line da more_horizontal